Merck, Pfizer well-placed for spinoff benefits

U.S. investors have been pressuring companies to return cash to shareholders via spinoffs, and Goldman Sachs points to Merck ($MRK) and Pfizer ($PFE) as two firms that could benefit most from asset sales. Pfizer is exploring options for its animal health and nutritionals businesses. Report

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.